Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Merger or Acquisition (April 2026)
9 slides from Gujarat Themis Biosyn's merger presentation, Apr 23, 2026
Slide 1: Gujarat Themis Biosyn Limited – Investor Presentation filing letter
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2026-27/06 23rd April, 2026 Corporate Relationship Department Listing Department B
Slide 2: Gujarat Themis Biosyn Limited Portfolio Acquisition
Gujarat Themis Biosyn Limited Portfolio Acquisition
Slide 3: Agreement with Sanofi to Acquire Select Product Portfolio
Agreement with Sanofi (the French-holding company of the Sanofi group) to Acquire Select Product Portfolio Asset acquisition structured for immediate global market access after closing 13 55+ ~EURO 62M ESTABLISHED GLOBAL BRANDS COUNTRIES REACHED PORTFOLIO REVENUE FY 2025 DEAL STRUCTURE ACQUISITION H
Slide 4: Key molecules and market presence
Branded Generics Products Across TB & Anti-Infective Therapies to be added PORTFOLIO METRICS KEY M O L E C U L E S Rifampicin Rifapentine Levofloxacin PRODUCTS IN PORTFOLIO 13 GLOBAL REACH (COUNTRIES) 55+ MARKET P R E S E N C E EUROPE MIDDLE EAST RETAIL CHANNEL CONTRIBUTION ~70% AFRICA 55+ COUNTRIES
Slide 5: Driving Global Scale and Value Chain Integration after closing
Driving Global Scale and Value Chain Integration after closing Global Expansion Forward Integration • Complement existing fermentation strength with API • Access to 55+ countries and finished formulations • Strong presence in Europe & MEA • Leverage in-house capabilities • Entry into regulated + hig
Slide 6: Resilient Financials Backed by Structural Demand
Resilient Financials Backed by Structural Demand ~EURO 62M FAVOURABLE MARKET DYNAMICS Global TB Burden PORTFOLIO REVENUE Tuberculosis remains one of the world's leading infectious FY 2025 disease killers, driving sustained demand for anti-TB therapies. HEALTHY GROSS MARGINS With expansion potential
Slide 7: Management Speak
Management Speak “This acquisition would be a strategic milestone in GTBL’s evolution toward a high- margin, fermentation-based pharmaceutical platform serving many patients in multiple regions. By leveraging our core competencies in fermentation-based product portfolio, we Commenting on this are tr
Slide 8: Multiple Levers to Unlock Post Closing Value
Multiple Levers to Unlock Post Closing Value High-Burden Lifecycle Dormant MA Distribution Portfolio Market Expansion Management Reactivation Network Leverage Optimization & Brand Scaling Expansion into under- Development of new Systematic identification Leveraging the acquired penetrated markets fo
Slide 9: Thank You
Thank You For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Krupesh Patel Mr. Rahul Trivedi Chief Financial Officer Ms. Saloni Nagvekar krupesh.patel@themismedicare.com rahul.trivedi@adfactorspr.com saloni.nagvek
Gujarat Themis Biosyn — Merger or Acquisition (April 2026) on 6ix